Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Johnson & Johnson reported Q3 results on October 13 and the stock dropped 5.7% on the day, closing at $248.61. The print delivered revenue of $25.49bn and EPS of $2.49, broadly in line with consensus but weighed down by a $1.785bn IPR&D charge tied to the Firefly and Sail acquisitions. After weeks of previews noting the gap between analyst conviction and price action, the market answered the question: the stock had not absorbed all the good news.
The two analysts who moved first this morning both trimmed targets without changing their positive ratings. Wells Fargo's Larry Biegelsen cut to $275 from $282 while maintaining Overweight, and RBC Capital's Trung Huynh lowered to $280 from $290 on his Outperform. That reverses RBC's target raise just eight days earlier, when Huynh had lifted to $290. The mean consensus target now stands at $278.68, which leaves roughly 12% implied upside from the $248.61 close. That gap is actually wider than before the print, a function of the price falling faster than targets. The broader analyst posture remains constructive: Citigroup, HSBC, UBS, and Guggenheim all carry Buy-equivalent ratings with targets ranging from $275 to $320, none of which have been updated since the print. JP Morgan sits at Neutral with a $285 target. The direction of travel from the Street is still positive, even if the pace of upgrades has stalled for now.
The bear case, as laid out in the snapshot, centres on exactly what happened: a print that was only "broadly in line", compounding concerns about loss of exclusivity, slower MedTech growth, and pipeline traction on newer assets including Inlexzo, Rybrevant, and nipocalimab. The 2026E outlook of $101.01bn in sales and $11.05 EPS sits near the middle of guidance, leaving limited room for positive surprises. Drug pricing reform and talc litigation remain in the background. Bulls counter with the durability of the Innovative Medicine portfolio, where Darzalex, Tremfya, and Caplyta continue to deliver, and with the company's ability to generate strong cash flow after the consumer divestiture. The EV/EBITDA multiple has compressed roughly 1.7 turns over the past 30 days, now at 16.2x, while the P/E has pulled back about a point to 21.1x. Valuations are moving toward the stock rather than away from it.
Positioning in the lending market is a non-story, and that remains unchanged from the pre-earnings notes. Short interest is less than 1% of the free float at 0.87%, and borrow costs have actually fallen sharply, down 42% on the week to just 0.31%. Share availability is effectively unlimited. Whatever drove the 5.7% decline on Tuesday, it was not short sellers with elevated conviction. Options are running slightly below their 20-day average on the put/call ratio at 0.80, a mild negative z-score of -0.62, suggesting the options market was not particularly hedged into the print. The short score of 31.1 is low in absolute terms and places JNJ at the 81st percentile for short score rank, meaning the borrow and lending data offers no amplifying signal either way.
One structural note worth tracking: ORTEX puts a 60% probability on a share-count decrease for JNJ across the Russell 3000, Russell 1000, and S&P 500 in connection with a pending spinoff of the orthopaedics business. The estimated announcement date is July 9, 2027, with an effective date of July 14, 2027, though ORTEX flags those dates as estimated. A spinoff of this kind would reduce JNJ's index weighting in all three benchmarks, mechanically forcing tracker funds to reduce exposure. The next earnings event is not until January 19, 2027, leaving three months for the Street to recalibrate targets and for the spinoff timeline to sharpen. The question now is whether the $278 consensus holds or follows the stock lower.
See the live data behind this article on ORTEX.
Open JNJ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
